Why Shares of CorMedix Are Slumping Thursday

What happened

Shares of CorMedix (NASDAQ:CRMD) were down more than 21% as of noon ET on Thursday. The shares fell after the company announced a stock sale. The healthcare stock is down more than 5% so far this year.

So what

The stock sale was actually a double whammy of dilution for investors of the pharmaceutical and medical device company. CorMedix is selling 7.5 million shares of common stock at $4 per share, a 21.4% discount at what the stock closed at on Wednesday. The company also is offering prefunded warrants of up to 2.5 million shares at $3.99 per warrant. All together, the sales should bring $40 million in funding to CorMedix.

Now what

CorMedix recently resubmitted a New Drug Application (NDA) for DefenCath to the Food and Drug Administration. The FDA accepted the resubmission on June 21 and set up a six-month review with a Prescription Drug User Fee Act (PDUFA) target action date of Nov. 15.

The therapy is an antibacterial and antifungal solution that is supposed to prevent catheter-related infections in end-stage kidney patients who are receiving dialysis through a catheter. The therapy is already approved in Europe under the brand name Neutrolin. CorMedix, as of the first quarter, said it only had $55.6 million in cash, enough, it said at the time, to fund operations only into the first half of 2024,

The company likely sees the stock sale as a way to help fund operations as it ramps up the regulatory process and possibly, the commercialization of DefenCath. In a phase 3 study, the therapy showed a 71% decrease in catheter-related bloodstream infections, compared to a control group.

10 stocks we like better than CorMedix
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and CorMedix wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 26, 2023

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.